vs

Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Service Properties Trust (SVC). Click either name above to swap in a different company.

Service Properties Trust is the larger business by last-quarter revenue ($296.5M vs $168.4M, roughly 1.8× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs -17.0%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -6.1%).

Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.

Medical Properties Trust, Inc. (MPT) is an international real estate investment trust (REIT) based in Birmingham, Alabama that purchases and invests in healthcare facilities and for-profit healthcare holding companies, primarily in the United States and Europe. Their property acquisitions often come in the form of sale-leaseback agreements, in which the original property owner sells the property to MPT and becomes their tenant. MPT's tenants are generally subject to long-term triple net lease...

ESPR vs SVC — Head-to-Head

Bigger by revenue
SVC
SVC
1.8× larger
SVC
$296.5M
$168.4M
ESPR
Growing faster (revenue YoY)
ESPR
ESPR
+160.7% gap
ESPR
143.7%
-17.0%
SVC
Faster 2-yr revenue CAGR
ESPR
ESPR
Annualised
ESPR
10.6%
-6.1%
SVC

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
ESPR
ESPR
SVC
SVC
Revenue
$168.4M
$296.5M
Net Profit
$-782.0K
Gross Margin
Operating Margin
50.6%
-3.9%
Net Margin
-0.3%
Revenue YoY
143.7%
-17.0%
Net Profit YoY
99.0%
EPS (diluted)
$0.32
$-0.01

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ESPR
ESPR
SVC
SVC
Q4 25
$168.4M
$296.5M
Q3 25
$87.3M
$377.6M
Q2 25
$82.4M
$404.4M
Q1 25
$65.0M
$335.0M
Q4 24
$69.1M
$357.0M
Q3 24
$51.6M
$390.9M
Q2 24
$73.8M
$412.5M
Q1 24
$137.7M
$336.2M
Net Profit
ESPR
ESPR
SVC
SVC
Q4 25
$-782.0K
Q3 25
$-31.3M
$-46.9M
Q2 25
$-12.7M
$-38.2M
Q1 25
$-40.5M
$-116.4M
Q4 24
$-76.4M
Q3 24
$-29.5M
$-46.9M
Q2 24
$-61.9M
$-73.8M
Q1 24
$61.0M
$-78.4M
Operating Margin
ESPR
ESPR
SVC
SVC
Q4 25
50.6%
-3.9%
Q3 25
-11.4%
-12.8%
Q2 25
8.6%
-9.2%
Q1 25
-34.0%
-33.3%
Q4 24
-6.4%
-19.4%
Q3 24
-31.0%
-12.8%
Q2 24
3.5%
-17.1%
Q1 24
52.5%
-21.4%
Net Margin
ESPR
ESPR
SVC
SVC
Q4 25
-0.3%
Q3 25
-35.9%
-12.4%
Q2 25
-15.4%
-9.4%
Q1 25
-62.2%
-34.8%
Q4 24
-21.4%
Q3 24
-57.2%
-12.0%
Q2 24
-83.9%
-17.9%
Q1 24
44.3%
-23.3%
EPS (diluted)
ESPR
ESPR
SVC
SVC
Q4 25
$0.32
$-0.01
Q3 25
$-0.16
$-0.28
Q2 25
$-0.06
$-0.23
Q1 25
$-0.21
$-0.70
Q4 24
$-0.14
$-0.46
Q3 24
$-0.15
$-0.28
Q2 24
$-0.33
$-0.45
Q1 24
$0.34
$-0.48

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ESPR
ESPR
SVC
SVC
Cash + ST InvestmentsLiquidity on hand
$167.9M
$346.8M
Total DebtLower is stronger
$5.5B
Stockholders' EquityBook value
$-302.0M
$646.1M
Total Assets
$465.9M
$6.5B
Debt / EquityLower = less leverage
8.52×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ESPR
ESPR
SVC
SVC
Q4 25
$167.9M
$346.8M
Q3 25
$92.4M
$417.4M
Q2 25
$86.1M
$63.2M
Q1 25
$114.6M
$80.1M
Q4 24
$144.8M
$143.5M
Q3 24
$144.7M
$48.6M
Q2 24
$189.3M
$14.6M
Q1 24
$226.6M
$71.3M
Total Debt
ESPR
ESPR
SVC
SVC
Q4 25
$5.5B
Q3 25
Q2 25
Q1 25
Q4 24
$5.8B
Q3 24
Q2 24
Q1 24
Stockholders' Equity
ESPR
ESPR
SVC
SVC
Q4 25
$-302.0M
$646.1M
Q3 25
$-451.4M
$647.9M
Q2 25
$-433.5M
$695.9M
Q1 25
$-426.2M
$734.6M
Q4 24
$-388.7M
$851.9M
Q3 24
$-370.2M
$929.0M
Q2 24
$-344.2M
$1.0B
Q1 24
$-294.3M
$1.1B
Total Assets
ESPR
ESPR
SVC
SVC
Q4 25
$465.9M
$6.5B
Q3 25
$364.0M
$7.0B
Q2 25
$347.1M
$6.9B
Q1 25
$324.0M
$7.0B
Q4 24
$343.8M
$7.1B
Q3 24
$314.1M
$7.1B
Q2 24
$352.3M
$7.1B
Q1 24
$373.1M
$7.2B
Debt / Equity
ESPR
ESPR
SVC
SVC
Q4 25
8.52×
Q3 25
Q2 25
Q1 25
Q4 24
6.85×
Q3 24
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ESPR
ESPR
SVC
SVC
Operating Cash FlowLast quarter
$45.2M
$-18.5M
Free Cash FlowOCF − Capex
$-95.2M
FCF MarginFCF / Revenue
-32.1%
Capex IntensityCapex / Revenue
0.0%
25.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-107.0M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ESPR
ESPR
SVC
SVC
Q4 25
$45.2M
$-18.5M
Q3 25
$-4.3M
$98.1M
Q2 25
$-31.4M
$-7.0K
Q1 25
$-22.6M
$38.2M
Q4 24
$-35.0M
$-9.7M
Q3 24
$-35.3M
$106.2M
Q2 24
$-7.2M
$43.8M
Q1 24
$53.8M
$-926.0K
Free Cash Flow
ESPR
ESPR
SVC
SVC
Q4 25
$-95.2M
Q3 25
$57.9M
Q2 25
$-46.6M
Q1 25
$-23.2M
Q4 24
$-88.9M
Q3 24
$-35.5M
$24.1M
Q2 24
$-7.3M
$-22.3M
Q1 24
$53.8M
$-77.2M
FCF Margin
ESPR
ESPR
SVC
SVC
Q4 25
-32.1%
Q3 25
15.3%
Q2 25
-11.5%
Q1 25
-6.9%
Q4 24
-24.9%
Q3 24
-68.7%
6.2%
Q2 24
-9.9%
-5.4%
Q1 24
39.0%
-23.0%
Capex Intensity
ESPR
ESPR
SVC
SVC
Q4 25
0.0%
25.9%
Q3 25
0.0%
10.6%
Q2 25
0.0%
11.5%
Q1 25
0.0%
18.3%
Q4 24
0.0%
22.2%
Q3 24
0.3%
21.0%
Q2 24
0.1%
16.0%
Q1 24
0.1%
22.7%
Cash Conversion
ESPR
ESPR
SVC
SVC
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ESPR
ESPR

Collaboration Revenue$124.7M74%
Products$43.7M26%

SVC
SVC

Segment breakdown not available.

Related Comparisons